Nxera Pharma

Nxera Pharma is a technology-powered biopharma company dedicated to improving the lives of patients with unmet needs in Japan and globally. With a history dating back to 1990, the company has established itself as a prominent player in the industry. Nxera Pharma is actively involved in commercializing several products in Japan and is simultaneously pursuing an extensive pipeline of over 30 active programs from discovery through to late clinical stage, both internally and in partnership with leading pharma and biotech companies. The company's focus areas encompass neurology, GI and immunology, metabolic disorders, and rare diseases, leveraging its unique and industry-leading GPCR-targeted structure-based drug discovery "NxWave" platform to provide a sustainable source of best- or first-in-class candidates. Nxera Pharma boasts a team of over 350 talented individuals located at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland), and Seoul (South Korea). As a testament to its growth and success, Nxera Pharma is listed on the Tokyo Stock Exchange (ticker: 4565). With a focus on cutting-edge technology and addressing critical medical needs, Nxera Pharma presents an exciting opportunity for venture capital investors aiming to make a significant impact in the biopharma sector.